Oric Pharmaceuticals
Brooke Jackson is a quality assurance professional with extensive experience in the pharmaceutical and healthcare industries. Currently serving as a Quality Assurance Systems Manager at ORIC Pharmaceuticals Inc. since February 2022, Brooke previously held the role of Quality Assurance Specialist in the same company. Prior experience includes positions as a Quality Assurance Associate at OLLY PBC, a Quality Associate at Qualomics, LLC, and a Senior QA Associate at RTI Surgical®. Earlier in the career, Brooke worked as a Certified Nursing Assistant at both Palm Gardens of Gainesville and Eldercare Services. Brooke holds an Associate of Arts degree from Santa Fe College, earned between 2005 and 2011.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.